DNA in Medical Technology

Ancestry.com DNA Testing Reveals 'Roots' Author's Scottish Ancestry

Nephew of Alex Haley Meets Newfound Scottish Cousin for the First Time PROVO, Utah, April 7 /PRNewswire/ -- Ancestry.com, the world's largest online resource for family history, announced today that the late Alex Haley, author of Roots - the decisive masterpiece that inspired many Americans...

Study Shows How Defective DNA Repair Triggers Two Neurological Diseases

St. Jude scientists' findings in ataxia telangiectasia-like disease and Nijmegen breakage syndrome offer insight into the links between brain disease and cancer vulnerability in people carrying the diseases MEMPHIS, Tenn., Jan. 14 /PRNewswire-USNewswire/ -- Scientists at St. Jude Children's...

Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial

SAN DIEGO, Dec. 1 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL ) announced today the receipt of a $1.0 million milestone payment from Merck & Co., Inc. based on Merck's planned initiation of a Phase I clinical trial of an investigational plasmid DNA (pDNA) cancer vaccine. The c...

U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vical's Vaxfectin(R) Adjuvant

SAN DIEGO, Nov. 6 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced that the Naval Medical Research Center (NMRC) plans to conduct preclinical and Phase 1 evaluation of a dengue DNA vaccine formulated with the company's Vaxfectin(R) adjuvant and delivered with the Bio...

Researchers at Axial Biotech Develop a DNA Test for Scoliosis

Study results presented at the Scoliosis Research Society Meeting in Salt Lake City SALT LAKE CITY, Sept. 11 /PRNewswire/ -- Researchers at Axial Biotech, Inc., announced today that they have identified specific genetic markers for scoliosis. The data from this res...

febit and TGen Collaborate to Study New DNA Capture Method

febit's HybSelect(TM) Technology Evaluated to Enable Targeting and Increase Speed for Next-Generation-Sequencing LEXINGTON, Mass. and HEIDELBERG, Germany, Aug. 14 /PRNewswire/ -- febit and the Translational Genomics Research Institute (TGen) today announced the formation of a co...

New Research Shows One in 200 People Born with DNA Mutation That Can Lead to Devastating, Often Fatal Disease

Mutation Causing Mitochondrial Disease More Common Than Previously Believed PITTSBURGH, Aug. 11 /PRNewswire-USNewswire/ -- The United Mitochondrial Disease Foundation (UMDF) today announced landmark research finding that one in every 200 people has a DNA mutation that could potentially cause...

Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data

SAN DIEGO, July 17 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL ) today announced a breakthrough with preliminary clinical trial data demonstrating that DNA vaccines can safely achieve significant immune responses against H5N1 pandemic influenza in humans. DNA vaccines are funda...

Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH

SAN DIEGO, June 25 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL ) today announced that the company has successfully completed first-year milestones under a three-year, $6.0 million grant awarded in 2007, and is advancing with the development of a DNA vaccine manufacturing proces...

BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer

- Memorial Sloan-Kettering Cancer Center Investigators to Assess BSI-201 Therapy in BRCA-Negative Ovarian Cancer Patients - BRISBANE, Calif., May 8 /PRNewswire/ -- BiPar Sciences, Inc. today announced the expansion of Phase 2 clinical trial programs for its lead product, BSI-201, in ...

SuperGen's DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine

Restored sensitivity to cisplatin observed in ovarian carcinoma xenografts DUBLIN, Calif., April 14 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematologi...

BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer

- Strategic Collaboration with the National Cancer Institute's NABTT Consortium - BRISBANE, Calif., April 10 /PRNewswire/ -- BiPar Sciences, Inc. today announced the expansion of the clinical program for the company's lead product candidate, BSI-201, into gliobla...

Vical Receives NIH Grant for an Immunotherapeutic Herpes DNA Vaccine; Herpes Experts at University of Washington and University of Texas to Conduct Preclinical Development

SAN DIEGO, April 3, 2008 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL ) today announced that it has been awarded a two-year, $2.0 million Phase II Small Business Technology Transfer (STTR) grant from the U.S. National Institute of Allergy and Infectious Diseases (NIAID) of the N...

Interim Safety Data Favorable for Vical's Phase 2 Trial of DNA Vaccine Against CMV

SAN DIEGO, Oct. 17 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL ) today announced that an independent data safety monitoring board (DSMB) found no safety issues and recommended continuation of the company's Phase 2 trial of a DNA vaccine against cytomegalovirus (CMV). The DSMB c...

Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis

SEATTLE, Sept. 17 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation (Nasdaq: TGEN ) today reported on the public hearing conducted by the National Institutes of Health (NIH) Recombinant DNA Advisory Committee (RAC), which reviewed the serious adverse event reported by Targeted Genetics ...

Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza

SAN DIEGO, Aug. 28 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL ) today announced the enrollment of the first subject in its Phase 1 trial of the company's Vaxfectin(TM)-formulated plasmid DNA (pDNA) pandemic influenza vaccine. The double-blind, placebo-controlled trial will eva...

Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms

NEW YORK, Aug. 14 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Amex: IMM ) commented today on a recent paper published in Nucleic Acids Research by a group of researchers at the National Cancer Institute on the ability of furamidine to inhibit a key enzyme involved in the DNA repa...

Study Reports Successful Cloning of Human Embryo Using Adult DNA

Key Step Toward Developing Embryonic Stem Cell Lines for Therapeutic Cloning DURHAM, N.C., Jan. 17 /PRNewswire/ -- A California research team has become the first to report, and painstakingly document, the cloning of a human embryo using donated oocytes (egg ce...

Inovio Biomedical's DNA Delivery Technology Significantly Enhances Potency of HIV DNA Vaccine

SAN DIEGO--(BUSINESS WIRE)--Mar 26, 2007 - Inovio Biomedical Corp. (AMEX:INO), which is focused on the development of DNA vaccines and a novel solid tumor ablation therapy, announced today that the Journal of Virology has published a scientific paper prepared by Inovio's development partner, Wyeth,...

Interferon Beta DNA Treatment Delivered with Ichor Technology Reduces Atherosclerosis Progression in Mice

Summary: Proprietary DNA delivery technology enables sustained Interferon-beta production from muscle cells - reduces atherosclerosis progression in mouse model of heart disease NEW ORLEANS--(BUSINESS WIRE)--Mar 26, 2007 - Research conducted at Cleveland Clinic and presented today at the American ...

Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51

Other Presentations at AACR Highlight Progress in SuperGen's Oncology-Focused Pre-Clinical Pipeline LOS ANGELES, April 19, 2007 /PRNewswire-FirstCall/ -- SuperGen Inc. today announced that MP470, its multi-targeted tyrosine kinase inhibitor, suppresses the Rad51 protein, a critical component of do...

Inovio: DNA delivery technology shows positive human results

Inovio Biomedical’s DNA Delivery Technology Significantly Enhances Potency of Gene-Based Prostate Cancer Vaccine Key Milestone for First-in-Man DNA Vaccine Clinical Trial Using Inovio’s Electroporation DNA Delivery Technology SAN DIEGO, May 22, 2007 -- Inovio Biomedical Corp. (...

CytoGenix to Present at 2007 International DNA Vaccines Conference in Spain

HOUSTON--(BUSINESS WIRE)--May 23, 2007 - CytoGenix, Inc. (CYGX.OB) announced today that Dr. Yin Chen, Chief Scientific Officer will present an update on preclinical animal data for DNA vaccines made using the Company's proprietary synDNA(TM) technology at the 2007 DNA Vaccines conference to be held...

VGX Pharmaceuticals' Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models

MALAGA, Spain--(BUSINESS WIRE)--May 23, 2007 - VGX Pharmaceuticals' novel pandemic influenza vaccine candidates triggered protective immune responses in pre-clinical challenge studies, according to data presented for the first time today at the Third International Conference on DNA Vaccines in Mala...

Inovio Biomedical's DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results

SAN DIEGO--(BUSINESS WIRE)--May 24, 2007 - Inovio Biomedical Corporation (AMEX:INO), focused on the development of DNA-based DNA vaccines for cancers and infectious diseases and a novel alternative to surgery to treat localized cancers, announced today that interim clinical trial results demonstrat...

Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates

SEATTLE, May 31, 2007 /PRNewswire-FirstCall/ -- Vical Incorporated today announced that a measles DNA vaccine formulated with the company's Vaxfectin(TM) adjuvant elicited protective levels of neutralizing antibodies in juvenile (1 - 2 year old) nonhuman primates confirmed by complete protection f...

Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting

SAN DIEGO--(BUSINESS WIRE)--Jun 6, 2007 - Inovio Biomedical Corporation (AMEX:INO), focused on the development of DNA vaccines for cancers and infectious diseases and a novel alternative to surgery to treat localized cancers, announced today the company delivered multiple presentations on preclinic...

Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedical's Electroporation DNA Delivery Technology

SAN DIEGO--(BUSINESS WIRE)--Jun 7, 2007 - Inovio Biomedical Corporation (AMEX:INO), focused on the development of DNA vaccines for cancers and infectious diseases and a novel alternative to surgery to treat localized cancers, announced today that the company's partner, Vical Incorporated, presented...

NIEHS Researchers Identify Enzyme Critical in DNA Replication

BETHESDA, Md., July 5, 2007--In this weeks issue of Science, researchers from the National Institute of Environmental Health Sciences (NIEHS) and Umeö University in Sweden report an important discovery about a critical new role that an enzyme called DNA polymerase epsilon plays in replicating...

DNA Helps Reunite Children With Their Families

...DS Project (Program for Kids Identification with dna Systems ). PROKIDS is an international humanitarian effort using dna testing to deter human trafficking of children and...r parents. Through the DNA-PROKIDS program, dna samples will be obtained from children associated ...

Researchers Create First Targeted Knockout Rats Using Zinc Finger Nuclease Technology

...ays and can result in site-specific changes in the dna sequence. Previously, ZFNs were used to knock out...s). By engineering ZFPs that recognize a specific dna sequence Sangamo has created ZFP transcription fac...d INSERM routinely generates transgenic rats using dna or lentiviral vector microinjection. The generati...

National Cancer Institute Research Identifies Unique Mechanism of Brostallicin's Anti-Tumor Effectiveness

...ptibility mechanisms for brostallicin, a synthetic dna minor grove binder, and to identify differences b...in, the NCI research indicates that the tumor cell dna damaging effects of brostallicin are enhanced by h...esistant tumors. Brostallicin was shown to affect dna in both dividing and quiescent cells. Its actions ...

UPDATE: US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201

...pears so far to be a well tolerated and effective therapy." BSI-201 targets PARP, or poly (ADP-ribose) polymerase, a key enzyme involved in dna repair and cell proliferation. By inhibiting the enzymatic activity of PARP, BSI-201 significantly enhances the anti-tumor effects of chemotherapy and...

University of Michigan Study Shows SEQUENOM's MassARRAY Technology Identifies HPV Infections Missed by Standard Hybridization Test

...ative by the HC2 test had detectable levels of HPV dna by the PCR-MS method," said Divya Patel, PhD, MPH,...from women who had been routinely screened for HPV dna using the HC2 test, the most widely used clinical ...egative by PCR-MS. In all these cases, degenerate dna sequencing failed to detect any of the 13 high-ris...

Is Obesity an Oral Bacterial Disease?

...ulations of overweight women. Saliva was collected from 313 women with a body mass index between 27 and 32, and bacterial populations were measured by dna probe analysis. Levels in this group were compared with data from a population of 232 healthy individuals from periodontal disease studies. The median...

Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech

...oping zinc finger DNA-binding protein (ZFP) technology for therapeutic gene regulation and modification. By engineering ZFPs that recognize a specific dna sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also...

More Gene Mutations Linked to Autism Risk

... several collaborating institutions. This study identified 27 different genetic regions where rare copy number variations - missing or extra copies of dna segments - were found in the genes of children with autism spectrum disorders (ASDs), but not in the healthy controls. The complex combination of mult...

GeoVax Labs, Inc. Announces Results of 2009 Annual Shareholders Meeting

...e largest worldwide clinical trials program dedicated to the development and testing of AIDS vaccines. Preclinical work enabling evaluation of GeoVax dna and MVA vaccines was funded and supported by NIAID, which provided additional support to GeoVax AIDS vaccine development program with a $17 million IP...

ADHD Genes Found; Known to Play Roles in Neurodevelopment

... -- Missing dna Segments May Suggest Future Drug Targets -- P...lecular Psychiatry . Unlike changes to single dna bases, called SNPs or "snips," the alterations exa... strongly influenced by genetics. Drawing on dna samples from the Children's Hospital pediatric net...

Gene Findings Unlocking Reasons for Neuroblastoma Risk

...wide study found that a copy number variation (CNV) -- a missing stretch of dna -- along a structurally weak location on chromosome 1 plays an important ro...nation's largest research and clinical programs in pediatric oncology. dna samples for both studies were provided by the Children's Oncology Group, a ...